XML 101 R52.htm IDEA: XBRL DOCUMENT v3.25.0.1
Equity (Tables)
 12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Summary of common stock
The following table describes the number of shares authorized, issued and outstanding of our common stock as of December 31, 2024, 2023 and 2022:
 As of December 31, 2024As of December 31, 2023As of December 31, 2022
(In millions)AuthorizedIssuedOutstandingAuthorizedIssuedOutstandingAuthorizedIssuedOutstanding
Common stock1,000.0 169.5 145.8 1,000.0 168.7 144.9 1,000.0 167.9 144.0 
Schedule of accumulated other comprehensive income (loss)
The following tables summarize the changes in AOCI, net of tax by component:
December 31, 2024
(In millions)Unrealized Gains (Losses) on Cash Flow Hedges,
Net of Tax		Unrealized Gains (Losses) on Pension Benefit Obligation,
Net of Tax		Currency
Translation
Adjustments,
Net of Tax		Total
Balance, December 31, 2023$(25.0)$(2.6)$(126.1)$(153.7)
Other comprehensive income (loss) before reclassifications80.8 (14.0)(45.1)21.7 
Amounts reclassified from AOCI(4.2)— — (4.2)
Net current period other comprehensive income (loss)76.6 (14.0)(45.1)17.5 
Balance, December 31, 2024$51.6 $(16.6)$(171.2)$(136.2)
December 31, 2023
(In millions)Unrealized Gains (Losses) on Securities Available for Sale, Net of TaxUnrealized Gains (Losses) on Cash Flow Hedges,
Net of Tax		Unrealized Gains (Losses) on Pension Benefit Obligation,
Net of Tax		Currency Translation Adjustments,
Net of Tax		Total
Balance, December 31, 2022$(15.7)$15.1 $(1.1)$(163.2)$(164.9)
Other comprehensive income (loss) before reclassifications2.3 (26.8)(1.5)37.1 11.1 
Amounts reclassified from AOCI13.4 (13.3)— — 0.1 
Net current period other comprehensive income (loss)15.7 (40.1)(1.5)37.1 11.2 
Balance, December 31, 2023$— $(25.0)$(2.6)$(126.1)$(153.7)
December 31, 2022
(In millions)Unrealized Gains (Losses) on Securities Available for Sale,
Net of Tax		Unrealized Gains (Losses) on Cash Flow Hedges,
Net of Tax
Gains (Losses) on Net Investment Hedges,
Net of Tax(1)
Unrealized Gains (Losses) on Pension Benefit Obligation,
Net of Tax		Currency Translation Adjustments,
Net of Tax		Total
Balance, December 31, 2021$(2.2)$53.8 $25.5 $(44.8)$(139.0)$(106.7)
Other comprehensive income (loss) before reclassifications(23.5)137.3 12.6 43.7 (83.1)87.0 
Amounts reclassified from AOCI10.0 (176.0)(38.1)— 58.9 (145.2)
Net current period other comprehensive income (loss)(13.5)(38.7)(25.5)43.7 (24.2)(58.2)
Balance, December 31, 2022$(15.7)$15.1 $— $(1.1)$(163.2)$(164.9)
(1) Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 3, Dispositions, to these consolidated financial statements.
Reclassification out of accumulated other comprehensive income
The following table summarizes the amounts reclassified from AOCI:
(In millions)Amounts Reclassified from AOCIIncome Statement Location
For the Years Ended December 31,
202420232022
Gains (losses) on securities available for sale$— $(17.0)$(12.6)Other (income) expense, net
— 3.6 2.6 Income tax (benefit) expense
Gains (losses) on cash flow hedges18.1 11.6 201.6 Revenue
(12.9)3.7 (5.5)Operating expense
(0.4)(0.3)(0.3)Other (income) expense, net
(0.6)(1.7)(19.8)Income tax (benefit) expense
Gains (losses) on net investment hedges(1)
— — 38.1 Other (income) expense, net
Currency translation adjustments— — (58.9)Other (income) expense, net
Total reclassifications, net of tax$4.2 $(0.1)$145.2 
(1) Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 3, Dispositions, to these consolidated financial statements.